{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:07:17Z","timestamp":1786122437264,"version":"build-2736575974"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Hyperuricemia (HUA) is a prevalent comorbidity in patients with heart failure with preserved ejection fraction (HFpEF) and is closely associated with disease progression and adverse outcomes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors can rapidly and sustainably reduce serum uric acid (SUA) levels and lower the incidence of HUA-related clinical events; however, their underlying mechanisms remain unclear. This study employed network pharmacology and molecular docking to systematically investigate the potential mechanisms of SGLT2 inhibitors in HFpEF patients with concomitant hyperuricemia, focusing on uric acid metabolism modulation and inflammation-related pathways. Additionally, a machine learning approach was applied to retrospectively analyze the effects of SGLT2 inhibitors on SUA levels, aiming to clarify the therapy\u2019s biological basis and clinical relevance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The SMILES structures of eleven SGLT2 inhibitors were retrieved from PubChem. Potential drug targets were predicted via the SwissTargetPrediction platform and intersected with HFpEF- and HUA-related targets obtained from OMIM and GeneCards to identify common targets. Protein\u2013protein interaction (PPI) networks were constructed using STRING to identify hub genes, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses using DAVID. Molecular docking with AutoDock Vina assessed binding affinities. Clinical data of HFpEF patients were collected, and a classification model based on 34 clinical variables was developed using the FLAML automated machine learning framework to predict SGLT2 inhibitor treatment status and changes in SUA. Model interpretability and feature importance were performed using SHAP analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven SGLT2 inhibitors acted on 32 targets associated with SUA reduction in HFpEF patients. Key pathways included tumor necrosis factor (TNF), advanced glycation end product\u2013receptor for advanced glycation end product (AGE\u2013RAGE), interleukin-17 (IL-17), and Kaposi\u2019s sarcoma-associated herpesvirus (KSHV) signaling. Molecular docking demonstrated favorable binding of SGLT2 inhibitors to core targets, including GAPDH, CASP3, ICAM1, ACE, DPP4, and AGTR1, with canagliflozin showing the strongest predicted binding affinity. Clinical data analyses identified uric acid and creatinine as the most important predictors in the machine learning model, reflecting their importance in model predictions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>By integrating network pharmacology and retrospective clinical analysis, this study elucidates the potential uric acid\u2013lowering mechanisms of SGLT2 inhibitors in HFpEF patients. The identified targets and pathways provide mechanistic insights into SGLT2 inhibitor pharmacology and support their therapeutic potential for managing hyperuricemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1726611","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T10:27:36Z","timestamp":1786098456000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of SGLT2 inhibitors on uric acid levels in patients with heart failure with preserved ejection fraction: integration of mechanisms and clinical evidence"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Zhejiang Provincial People's Hospital Bijie Hospital (The First People's Hospital of Bijie)","place":["Bijie, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Zhejiang Provincial People\u2019s Hospital Bijie Hospital","place":["Bijie, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qu","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhejiang Provincial People's Hospital Bijie Hospital (The First People's Hospital of Bijie)","place":["Bijie, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daping","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Zhejiang Provincial People\u2019s Hospital Bijie Hospital","place":["Bijie, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhejiang Provincial People's Hospital Bijie Hospital (The First People's Hospital of Bijie)","place":["Bijie, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1161\/CIRCULATIONAHA.123.065134","article-title":"Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial","volume":"148","author":"Borlaug","year":"2023","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics\u20142020 update: a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jacc.2022.11.006","article-title":"Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction","volume":"81","author":"Kosiborod","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","volume":"403","author":"Campbell","year":"2024","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jacc.2023.10.030","article-title":"Hyperuricemia and gout reduction by SGLT2 inhibitors in diabetes and heart failure: JACC review topic of the week","volume":"83","author":"Packer","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.119.041886","article-title":"Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood institute working group summary","volume":"141","author":"Shah","year":"2020","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1403242","DOI":"10.3389\/fcvm.2024.1403242","article-title":"Relationship between serum uric acid levels and uric acid lowering therapy with the prognosis of patients with heart failure with preserved ejection fraction: a meta-analysis","volume":"11","author":"Li","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejim.2021.04.001","article-title":"Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: analysis of the ESC-EORP heart failure long-term (HF LT) registry","volume":"89","author":"Ambrosio","year":"2021","journal-title":"Eur J Intern Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.amjcard.2020.04.026","article-title":"Comparison of characteristics and outcomes of patients with heart failure with preserved ejection fraction with versus without hyperuricemia or gout","volume":"127","author":"Carnicelli","year":"","journal-title":"Am J Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e716","DOI":"10.1016\/j.amjmed.2020.03.054","article-title":"Elevated uric acid prevalence and clinical outcomes in patients with heart failure with preserved ejection fraction: insights from relax","volume":"133","author":"Carnicelli","year":"","journal-title":"Am J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/j.jchf.2024.08.020","article-title":"Uric acid and SGLT2 inhibition with empagliflozin in heart failure with preserved ejection fraction: the EMPEROR-preserved trial","volume":"12","author":"Doehner","year":"2024","journal-title":"Heart Fail"},{"key":"B13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: mechanisms and advances in therapy","volume":"9","author":"Du","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamacardio.2022.5608","article-title":"Association of dapagliflozin use with clinical outcomes and the introduction of uric acid\u2013lowering therapy and colchicine in patients with heart failure with and without gout: a patient-level pooled meta-analysis of DAPA-HF and DELIVER","volume":"8","author":"Butt","year":"2023","journal-title":"JAMA Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s40265-022-01778-0","article-title":"Empagliflozin: a review in symptomatic chronic heart failure: JE frampton et al.","volume":"82","author":"Frampton","year":"2022","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e70727","DOI":"10.7759\/cureus.70727","article-title":"Dapagliflozin\u2019s role in heart failure: an overview of clinical trial evidence","volume":"16","author":"Khan","year":"2024","journal-title":"Cureus"},{"key":"B17","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3390\/ph17070929","article-title":"Examining the impact of ertugliflozin on cardiovascular outcomes in patients with diabetes and metabolic syndrome: a systematic review of clinical trials","volume":"17","author":"Pescariu","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.jacc.2022.08.718","article-title":"Dapagliflozin, atrial fibrillation, and heart failure with mildly reduced or preserved ejection fraction in deliver","volume":"80","author":"Butt","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B19","first-page":"375","article-title":"Chinese expert consensus on the diagnosis and treatment of heart failure with preserved ejection fraction (hfpef) 2023","volume":"38","author":"Zhou","year":"2023","journal-title":"Chin Circ J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1001\/jamacardio.2024.2435","article-title":"Verinurad plus allopurinol for heart failure with preserved ejection fraction: the amethyst randomized clinical trial","volume":"9","author":"Kitzman","year":"2024","journal-title":"JAMA Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"Hopkins","year":"2007","journal-title":"Nat Chem Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"434","DOI":"10.48550\/arXiv.2101.05374","article-title":"Flaml: a fast and lightweight automl library","volume":"3","author":"Wang","year":"","journal-title":"Proc Mach Learn Syst"},{"key":"B23","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41551-018-0304-0","article-title":"Explainable machine-learning predictions for the prevention of hypoxaemia during surgery","volume":"2","author":"Lundberg","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1152\/physrev.00022.2018","article-title":"Fundamental mechanisms of regulated cell death and implications for heart disease","volume":"99","author":"Del Re","year":"2019","journal-title":"Physiol Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s11255-020-02481-3","article-title":"A unifying model of glucotoxicity in human renal proximal tubular epithelial cells and the effect of the SGLT2 inhibitor dapagliflozin","volume":"52","author":"Eleftheriadis","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/cvr\/cvx182","article-title":"Identification of optimal reference genes for transcriptomic analyses in normal and diseased human heart","volume":"114","author":"Molina","year":"2018","journal-title":"Cardiovasc Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cellsig.2010.08.003","article-title":"The diverse functions of GAPDH: views from different subcellular compartments","volume":"23","author":"Tristan","year":"2011","journal-title":"Cell Signal"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e13436","article-title":"The clinical significance of circulating glucose-regulated protein 78, caspase-3, and C\/EBP homologous protein levels in patients with heart failure","author":"Zhao","year":"2023","journal-title":"Heliyon"},{"key":"B29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/heartjnl-2024-325205","article-title":"The ICAM1 p. K56M variant and risk of heart failure in chronic kidney disease: the chronic renal insufficiency cohort study","volume":"111","author":"Culler","year":"2025","journal-title":"Heart"},{"key":"B30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"B31","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.122.059150","article-title":"Renal and vascular effects of combined SGLT2 and angiotensin-converting enzyme inhibition","volume":"146","author":"Lytvyn","year":"2022","journal-title":"Circulation"},{"key":"B32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00210-019-01765-5","article-title":"Protective effect of dipeptidyl peptidase-4 inhibitors in testicular torsion\/detorsion in rats: a possible role of HIF-1\u03b1 and nitric oxide","volume":"393","author":"Abdelzaher","year":"2020","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ijcard.2017.11.035","article-title":"Unraveling the relationship between serum uric acid levels and cardiovascular risk","volume":"253","author":"Carluccio","year":"2018","journal-title":"Int J Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41420-021-00625-7","article-title":"Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NF\u03baB pathway","volume":"7","author":"Wang","year":"","journal-title":"Cell Death Discov"},{"key":"B35","doi-asserted-by":"publisher","first-page":"101478","DOI":"10.1016\/j.gendis.2024.101478","article-title":"Identification of ageing-associated gene signatures in heart failure with preserved ejection fraction by integrated bioinformatics analysis and machine learning","volume":"12","author":"Li","year":"2025","journal-title":"Genes Dis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/dom.14570","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis","volume":"24","author":"Hu","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12325-014-0126-8","article-title":"Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial","volume":"31","author":"Kadowaki","year":"2014","journal-title":"Adv Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.clinthera.2013.11.002","article-title":"Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study","volume":"36","author":"Ji","year":"2014","journal-title":"Clin Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13340-014-0164-0","article-title":"Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study: BRIGHTEN: double-b lind r andomized study of i pra g liflozin to sh ow its efficacy as monotherapy in T 2DM pati en ts","volume":"6","author":"Kashiwagi","year":"2015","journal-title":"Diabetol Int"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1016\/S2665-9913(19)30078-5","article-title":"The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS program","volume":"1","author":"Li","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1111\/dom.12957","article-title":"Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP\/INS): results of a 16-week randomized, double-blind, placebo-controlled multicentre trial","volume":"19","author":"Terauchi","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B42","doi-asserted-by":"publisher","first-page":"942125","DOI":"10.3389\/fcvm.2022.942125","article-title":"SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis","volume":"9","author":"Yang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"875327","DOI":"10.3389\/fcvm.2022.875327","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors for heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized clinical trials","volume":"9","author":"Zhou","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.2147\/JIR.S429096","article-title":"Integration of rna-seq and machine learning identifies hub genes for empagliflozin benefitable heart failure with reduced ejection fraction","volume":"16","author":"Yang","year":"2023","journal-title":"J Inflamm Res"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1726611\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T10:27:37Z","timestamp":1786098457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1726611\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":44,"alternative-id":["10.3389\/fcvm.2026.1726611"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1726611","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"article-number":"1726611"}}